ARASENS: Darolutamide Plus ADT and Docetaxel May Become New Standard of Care for mHSPC
Hormonal Therapy for mCSPC: With So Many Options, How Does One Choose?
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer | NEJM
Launch of ARANOTE Study Augments Development Program for Darolutamide in Prostate Cancer
Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data - Bayer News
EAU 2019: Conclusions from Recent Oncology Meetings Regarding: Hormone Naïve Prostate Cancer
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer | NEJM
Darolutamide For Castration-Resistant Prostate Cancer. - Abstract - Europe PMC
ASCO GU 2018: TPS383 - ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-sensitive Prostate Cancer
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer | NEJM
Recent Advances in the Management of Metastatic Prostate Cancer | JCO Oncology Practice
ARASENS: Darolutamide Plus ADT and Docetaxel May Become New Standard of Care for mHSPC
ASCO GU 2022: Discussion on the ARASENS and PRESIDE Trials
Ravi A Madan M.D. on Twitter: "Dr. Mathew Smith presents data from #ARASENS trial of ADT+Docetaxel +/- Darolutamide in #mCSPC. Like #PEACE1 @ ESMO data favors triple combination. Are docs are willing
Selected Ongoing Trials With Darolutamide In Prostate Cancer | Download Scientific Diagram
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer | NEJM
Rapid Readout: ARASENS: Darolutamide Versus Placebo in Combination With ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment | American Society of Clinical Oncology Educational Book
Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data
Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial
ASCO GU 2022: ARASENS Trial Overall Survival With Darolutamide Versus Placebo in Combination With ADT and Docetaxel for mHSPC
Nubeqa (darolutamide) increases overall survival in men with mCSPC/HSPC when added to androgen-deprivation treatment (ADT) with docetaxel: ARASENS phase III study - DelveInsight Business Research
mHSPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
Updates and Insights on the Medical Science of Prostate Cancer (Transcript)
